Publications

5440 Results

Phase II clinical trial of IL-2/LAK in metastatic renal cancer.

Authors
RI Fisher
Journal / Conference
ASCO :#C959
Year
1987
Research Committee(s)
Genitourinary

Phase II study of high dose interleukin-2 (IL-2) and lymphokineactivated killer (LAK) cells in patients (pts) with melanoma.

Authors
JP Dutcher;S Creekmore;GR Weiss;K Margolin;AB Markowitz;MA Roper;D Parkinson
Journal / Conference
ASCO 6:246(#970)
Year
1987
Research Committee(s)
Melanoma

Phase II trial of continuous infusion cytarabine (ARA-C) and bolus cis-platin (CDDP) in advanced solid tumors: renal, gastric, esophageal, pancreatic, and unknown primary cancers.

Authors
L Leong;J Doroshow;S Akman;B Carr;D Goldberg;K Margolin
Journal / Conference
ASCO :#C-549
Year
1987

Hepatitis a (HAV) infection occurring following IL-2/LAK cell therapy.

Authors
DR Parkinson;DR Snydman;T Weisfuse;B Werner;D Graham;M Will;S Marcus;D Boldt;JH Doroshow;A Rayner;A Glover;R Fisher
Journal / Conference
ASCO :#C-922
Year
1987

Toxicity (TOX) of interleukin-2 and lymphokine-activated killer (LAK) cell therapy.

Authors
K Margolin;HS Jaffe;M Hawkins;MB Atkins;N Ciobanu;S Creekmore;C Coltman, Jr
Journal / Conference
ASCO :#C-988
Year
1987

Quality Control (QC) of the Community Clinical Oncology Program (CCOP) institutions within the Southwest Oncology Group (SWOG).

Authors
NH Brown;GR Weiss;C Coltman, Jr
Journal / Conference
ASCO :#C-906
Year
1987

Response assessment errors for all Southwest Oncology Group (SWOG) clinical trials are more likely overestimates of response.

Authors
GR Weiss;SK Kuebler;DL Kisner;C Coltman, Jr
Journal / Conference
ASCO :#C-894
Year
1987

Current Cancer and Leukemia Group B (CALGB) trials in the treatment of active hairy cell leukemia (HCL): A status report.

Authors
K Rai;R Mick;H Ozer;CD Bloomfield
Journal / Conference
Proc of the Fourth Intl Symp on Therapy of Acute Leukemias-Rome :250(233)
Year
1987
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8694 (CALGB-8582) (NSC-377523) (NSC-218321)

Effect of age on therapeutic outcome in advanced diffusehistiocytic lymphoma: the Southwest Oncology Group experience.

Authors
DO Dixon;BA Neilan;SE Jones;DA Lipschitz;TP Miller;SE Salmon;PN Grozea;SP Balcerzak
Journal / Conference
JCO 4(3):296-305
Year
1986
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7426/7427, SWOG-7713/14

What should be the morphologic criteria for the subdivision offollicular lymphomas?

Authors
BN Nathwani;GE Metter;TP Miller;JS Burke;RB Mann;M Barcos;CR Kjeldsberg;DO Dixon;CD Winberg;CC Whitcomb;SE Jones
Journal / Conference
Blood 68(4):837-845
Year
1986
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7426/7427, SWOG-7713/14